BioRestorative Therapies

BioRestorative Therapies EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioRestorative Therapies (BRTX) as of Nov 5, 2026 is -15.65 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -11.56 M USD — a change of 35.41% (lower).

EBITDA

-15.65 MUSD

YoY

35.41%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioRestorative Therapies is 2025 -15.65 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioRestorative Therapies was 2024 -11.56 M USD. It decreases by 35.41% lower compared to the previous year.

The BioRestorative Therapies EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-7.65 M USD
Jan 1, 2019
-8.43 M USD
Jan 1, 2020
-2.75 M USD
Jan 1, 2021
-26.31 M USD
Jan 1, 2022
-18.86 M USD
Jan 1, 2023
-15.22 M USD
Jan 1, 2024
-11.56 M USD
Jan 1, 2025
-15.65 M USD
The BioRestorative Therapies EBITDA history
YEAREBITDAYoY
-15.65 MUSD+35.41%
-11.56 MUSD-24.08%
-15.22 MUSD-19.31%
-18.86 MUSD-28.30%
-26.31 MUSD+855.93%
-2.75 MUSD-67.36%
-8.43 MUSD+10.26%
-7.65 MUSD-8.68%
-8.37 MUSD+7.40%
-7.80 MUSD+8.74%
-7.17 MUSD+45.66%
-4.92 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioRestorative Therapies Stock analysis

What does BioRestorative Therapies do? BioRestorative Therapies Inc generates revenue through the development and commercialization of cell-based therapeutic products. The company focuses on two primary programs: the Disc/Spine Program (brtxDISC) and the Metabolic Program (ThermoStem). Its lead product, BRTX-100, is a cell therapy formulated from autologous cultured mesenchymal stem cells derived from patients' bone marrow, designed for non-surgical treatment of lumbosacral disc disorders. The company also develops ThermoStem, a therapy using brown adipose-derived stem cells to create brown adipose tissue for metabolic conditions like obesity and diabetes. BioRestorative Therapies targets medical professionals and healthcare institutions seeking innovative cell therapies for chronic conditions, with its products in development stages focused on specific therapeutic applications. The company’s revenue model relies on the future commercialization of BRTX-100 and ThermoStem, with no current sales reported. Its proprietary production process for BRTX-100 involves collecting bone marrow, isolating and culturing stem cells, and cryopreserving them. ThermoStem’s development targets metabolic disorders, leveraging the company’s expertise in cell and tissue protocols. BioRestorative Therapies Inc operates as a life sciences firm specializing in adult stem cell therapies, with its products positioned for potential market entry in the biotechnology sector. BioRestorative Therapies Inc’s business strategy centers on advancing its pipeline of cell-based therapies, including BRTX-100 for disc disorders and ThermoStem for metabolic conditions. The company’s focus on proprietary technology and cell culture methods differentiates its approach within the biotechnology industry. While currently in development, its products aim to address unmet medical needs, targeting healthcare providers and patients with chronic conditions requiring non-surgical interventions. BioRestorative Therapies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioRestorative Therapies stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioRestorative Therapies is -15.65 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioRestorative Therapies changed from -11.56 M USD to -15.65 M USD, representing a 35.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) BioRestorative Therapies since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s BioRestorative Therapies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BioRestorative Therapies

All Key Metrics — BioRestorative Therapies